Lori Hazlehurst,Mark McLaughlin,Priyesh Jain,William S. Dalton
申请号：
US16113869
公开号：
US20180362583A1
申请日:
2018.08.27
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
